Compound ID | 1297
ALX-009 (Hypothiocyanite/Lactoferrin)
Class: Combination of bovine lactoferrin and hypothiocyanite
| Spectrum of activity: | Gram-negative |
| Details of activity: | Respiratory cystic fibrosis pathogens Pseudomonas aeruginosa and Burkholderia cepacia complex (Bcc). |
| Combined with other compounds: | Yes |
| Institute where first reported: | Halo Research Group, Queen’s University Belfast; School of Pharmacy, Queen’s University Belfast; Centre for Experimental Medicine, School of Medicine, Dentistry & Biomedical Science, Queen’s University Belfast; Alaxia SAS, Imperial College London and Royal Brompton Hospital. |
| Year first mentioned: | 2018 |
| Highest developmental phase: | Preclinical |
| Development status: | Active |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/126456119 |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/Hypothiocyanite |
| Citation: | https://academic.oup.com/jac/article-abstract/73/12/3391/5096850?redirectedFrom=fulltext |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.